Responders exhibited elevated levels of key taxa associated with anti-PD-1 response, along with heightened CD8+ T-cell activation and reduced frequency of interleukin-8-expressing myeloid cells, indicating a promising strategy for melanoma patients resistant to conventional anti-PD-1 therapy [297]. This evidence concerns the gene PDCD1 and melanoma.